Studies
The CTN+ supports clinical trials to find new ways to prevent, treat and manage HIV and other STBBIs, prioritizing a community-based approach of the highest scientific and ethical standards.
-
-
CTN 222: Canadian co-infection cohort
A prospective clinical cohort of HIV and hepatitis C virus co-infected patients
-
CTNPT 055: Testing Immunogenicity and Durability of Mpox Vaccination in People Living with HIV
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
-
CTNPT 048: The MOVE-UP Study
Mapping Opportunities for HPV Vaccination and Screening Engagement and Uptake in Trans Men and Gender Non-Binary Individuals Assigned Female at Birth
-
CTNPT 052: Glycoprotein 120 as a pan-toxin
Exploring the role of the soluble glycoprotein 120 as a pan-toxin driving immune dysfunction and accelerated aging in people living with HIV
-
CTN 338: PLATINUM-CAN
Placebo-controlled randomized trial of tecovirimat in non-hospitalized patients with Mpox: Canadian Feasibility Study
-
CTN 339: The NOVA-HIV Study
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living with HIV
-
-
CTNPT 043: Endocannabinoid system and inflamm-aging in HIV-associated atherosclerosis
Interplay between expanded endocannabinoid (eCB) system and inflamm-aging: Implication for accelerated atherosclerosis in people living with HIV (PLWH) under ART
-
CTNPT 047: Letermovir in ART-treated HIV-infected persons
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study
-
CTN 331: DDI Study: Drug-drug interactions between ART and feminizing hormones in trans women living with HIV
Drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.
Learn More